Study detail
RecruitingPhase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
Vanda Pharmaceuticals
Summary
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension
Eligibility
- Age range
- 18–65 years
- Sex
- All
- Healthy volunteers
- No
Detailed criteria
Inclusion Criteria: * SiSBP \>/= 130 mmHg despite \>8 weeks treatment w/ 1 or more antihypertensive therapies Exclusion Criteria: * Confirmed Grade 3/severe hypertension (SiSBP \>/= 180 mmHg, SiDBP \>/= 120 mmHg), unstable cardiac disease, renal insufficiency
Interventions
- Drugiloperidone
iloperidone
- DrugPlacebo
placebo comparator
Locations (28)
- Vanda Investigative SitePhoenix, Arizona
- Vanda Investigative SiteTempe, Arizona
- Vanda Investigative SiteTucson, Arizona
- Vanda Investigative SiteChula Vista, California
- Vanda Investigative SiteDublin, California
- Vanda Investigative SiteValencia, California